Christina Kay
2023
In 2023, Christina Kay earned a total compensation of $301.3K as Co, Chief Executive Officer at Integrated Biopharma, a 9% increase compared to previous year.
Compensation breakdown
Bonus | $6,400 |
---|---|
Option Awards | $48,225 |
Salary | $237,273 |
Other | $9,417 |
Total | $301,315 |
Kay received $237.3K in salary, accounting for 79% of the total pay in 2023.
Kay also received $6.4K in bonus, $48.2K in option awards and $9.4K in other compensation.
Rankings
In 2023, Christina Kay's compensation ranked 2,530th out of 3,006 executives tracked by ExecPay. In other words, Kay earned more than 15.8% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,530 out of 3,006 | 16th |
Division Manufacturing | 1,414 out of 1,650 | 14th |
Major group Chemicals And Allied Products | 817 out of 918 | 11th |
Industry group Drugs | 797 out of 881 | 10th |
Industry Pharmaceutical Preparations | 570 out of 637 | 11th |
Source: SEC filing on October 27, 2023.
Kay's colleagues
We found three more compensation records of executives who worked with Christina Kay at Integrated Biopharma in 2023.
News
Integrated Biopharma CFO Dina Masi's 2024 pay rises 8% to $357K
October 28, 2024
Integrated Biopharma CFO Dina Masi's 2023 pay rises 10% to $330K
October 27, 2023
Integrated Biopharma CFO Dina Masi's 2022 pay rises 12% to $300K
October 27, 2022
Integrated Biopharma CFO Dina Masi's 2021 pay rises 6% to $268K
October 27, 2021
Integrated Biopharma CFO Dina Masi's 2019 pay rises 4% to $251K
October 28, 2019